Takeaways: This acquisition turbocharges Hims & Hers’ Canada growth by giving it a ready-made weight-management business and local provider network, while it becomes the first Canadian...
Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for TEVIMBRA + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metas...
Takeaways: Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy. Market-wise, public funding acr...
Takeaways: Vimy Pharma’s filing could position it as a domestic, lower-cost semaglutide supplier in Canada, which supports affordability and national supply resilience. The broader market ...
Takeaways: Novo Nordisk is defending branded Ozempic’s market share by narrowing the price gap with generic semaglutide for uninsured Canadians. That should help reduce switching to lower-cost a...
Takeaways: Ontario’s reimbursement of BRAFTOVI is a meaningful win for Pfizer and a strong signal for precision oncology adoption in Canada. It should accelerate uptake in a biomarker-defined me...
Takeaways: IHEEZO gives Apotex a differentiated, in‑clinic anesthetic that strengthens its positioning with Canadian ophthalmologists and complements its anti‑inflammatory an...
Takeaways: Brain Canada is using these Platform Support Grants to build durable infrastructure in Western Canada that can change how brain and mental health research is done, not just fund singl...
Takeaways: HArmonyCa with Lidocaine positions Allergan Aesthetics to capture more of Canada’s growing demand for longer-lasting, non-surgical facial rejuvenation by offering both immediate ...
Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
